Neoadjuvant chemotherapy (NAC) for high-risk muscle-invasive bladder cancer (MIBC) is associated with a significantly higher pathologic complete response rate compared with upfront radical cystectomy, investigators reported in a poster presentation at the European Society for Medical Oncology 2019 Congress in Barcelona, Spain.
In a retrospective chart review of patients who underwent radical cystectomy (RC) for high-risk MIBC at their institution, Justin T. Matulay, MD, and colleagues at the University of Texas MD Anderson Cancer Center in Houston found a 29.9% and 23.9% rate of pathologic complete response among patients who received cisplatin-based and noncisplatin-based NAC, respectively, compared with an 8.2% rate among patients who did not receive NAC.
“These findings will serve as a benchmark for future neoadjuvant studies for evaluation of novel regimens,” the authors concluded.
The study population included 183 patients who did not receive NAC, 421 who received cisplatin-based NAC, and 69 who received noncisplatin-based NAC. The mean ages of the 3 groups were 72.6, 66.9, and 67.4 years, respectively. The median follow-up durations were 31.8, 31.0, and 47.8 months, respectively.
For the study, Dr Matulay and his collaborators included patients if they had at least 1 predefined high-risk feature (mixed variant histology, lymph node invasion, extravesical disease, and/or hydronephrosis).
Matulay JT, Campbell MT, Narayan VM, et al. Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle-invasive bladder cancer. Presented at the European Society for Medical Oncology 2019 Congress in Barcelona, Spain. Poster 924P.
This article originally appeared on Renal and Urology News